Shots:
- Iambic has partnered with Takeda in a multi-year tech & discovery collaboration to utilize Iambic’s AI drug discovery models toward advancing select high-priority small molecule programs in Takeda’s Oncology, & GI & Inflammation therapeutic areas
- The collaboration will leverage Iambic’s AI drug discovery suite & wet lab capabilities, with Takeda also gaining access to Iambic’s NeuralPLexer model for predicting protein-ligand complexes
- As per the deal, Iambic will receive upfront, research cost, & technology access payments & is eligible for milestone payments exceeding $1.7B, along with royalties on net sales of any products arising from the collaboration
Ref: Iambic | Image: Iambic & Takeda | Press Release
Related News: Takeda and Protagonist Therapeutics Report the US FDA’s NDA Submission for Rusfertide to Treat Polycythemia Vera
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
